Medicare AdvantagePrior AuthMedium impact
Sylvant® (siltuximab) (Revised)
Humana·FL, KY, SC · Hematology, Oncology, Infectious Disease·Medicaid
Effective date
Nov 26, 2025
We identified it
Jun 25, 2026
Summary
Humana revised its Sylvant® (siltuximab) prior authorization policy effective November 26, 2025, affecting Medicare and three state Medicaid programs (Florida, Kentucky, South Carolina). The policy maintains strict eligibility criteria requiring multicentric Castleman's disease diagnosis with HIV and HHV-8 negative status, specific lab values (ANC ≥1.0 x 10⁹/L, platelets ≥75 x 10⁹/L, hemoglobin <17 g/dL for initial; platelets ≥50 x 10⁹/L for renewal), and 6-month approval periods. No substantive coverage changes were made, but the revision date indicates policy review and potential clarification of existing requirements.
Action Required
By November 26, 2025: Billing and clinical teams must update prior authorization workflows for Sylvant claims. (1) Verify all claims for Sylvant intravenous solution include documentation of: multicentric Castleman's disease diagnosis, negative HIV and HHV-8 status, and baseline lab values (ANC, platelet count, hemoglobin). (2) Configure billing system to enforce prior authorization requirement for all Sylvant claims across Medicare and Medicaid (FL, KY, SC) lines of business. (3) Update prior auth submission templates to request initial 6-month approval periods. (4) For renewal requests, ensure documentation includes evidence of no disease progression/treatment failure and updated lab parameters (ANC ≥1.0 x 10⁹/L, platelets ≥50 x 10⁹/L, hemoglobin <17 g/dL). (5) Alert providers and specialty pharmacies that live vaccines cannot be administered to patients receiving Sylvant due to IL-6 inhibition effects. (6) Ensure clinical reviewers understand the 'Limitation of Use' section stating Sylvant is only indicated for HIV-negative and HHV-8-negative patients; claims for HIV-positive or HHV-8-positive patients will be denied. Failure to obtain prior authorization or submit required documentation will result in claim denials.